Short answer
TG THERAPEUTICS, INC. (TGTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers TG Therapeutics’ third-quarter and nine-month results through September 30, 2026.
TG THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers TG Therapeutics’ third-quarter and nine-month results through September 30, 2026
- Exhibit 99.1 contains the financial results and management commentary investors should review
- Results announcement provides the latest operating update for TGTX, with potential implications for revenue, expenses, cash position and guidance
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $259.9M, up from $161.7M, driven by BRIUMVI U.S. revenue $232.6M, up approximately 52% year over year
- Full-year 2026 revenue guidance raised to approximately $1B, with BRIUMVI U.S. guidance raised to $915–920M
- Operating income $85.9M, while net income $55.5M versus $390.9M last year due to the prior-year $365.0M tax benefit
- Cash, equivalents and investments $556.7M, supporting operations alongside commercial BRIUMVI revenue
- Approximately $100M repurchased in Q3, 2.0M shares at $49.43 average, signaling capital return and management confidence
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TG THERAPEUTICS, INC. 8-K filings
Get the next TGTX 8-K as it lands
Follow TGTX for push alerts, or ask the research agent what this filing means.